Skip to content

Updates

Explore our latest insights, regulatory updates, and strategic reports for the life sciences sector.

Type (1)
Blogs Testimonial
Sectors (2)
Agriculture Biotech Chemicals Cosmetics Diagnostics Digital Health Food and Feed Healthcare Medical Devices Pharmaceuticals
Expertises
Advertising and Claims Commercial Contracts Corporate, Governance and Boardroom Counselling Data Protection, (Cyber)security and AI Due Diligence Environmental and Sustainability Financing and M&A Intellectual Property and Licensing Litigation Regulatory Compliance and Enforcement Spin-out and Starter Advisory Subsidies and Grants
Testimonial Remove filter Cosmetics Remove filter Biotech Remove filter Clear all

14 results

Newest first
Newest first Oldest first A–Z Z–A
Agriculture Biotech Intellectual Property and Licensing Testimonial

Axon advised a Dutch joint venture, that is active within the agri-food and agricultural biotechnology sector, on the transfer of its assets to a German investment fund. The transferred assets involved patent rights, plant breeders’ rights, trade secrets and biological materials.

Biotech Pharmaceuticals Commercial Contracts Intellectual Property and Licensing Testimonial

Axon advised a stock-listed biopharmaceutical company on antibody licensing and technology transfer agreements with two major US-based pharmaceutical companies. The deals involved the grant of commercial rights to the licensor's proprietary antibody platform technology.

Biotech Corporate, Governance and Boardroom Counselling Financing and M&A Testimonial

Axon assisted a Dutch cultivated materials company in securing a EUR 22M Series A financing round. We advised on the transaction structure, investment documentation and related matters.

Biotech Diagnostics Corporate, Governance and Boardroom Counselling Due Diligence Financing and M&A Testimonial

Axon acted on behalf of an investor in connection with their investment in a clinical-stage biotech company developing first-in-class therapeutics and diagnostics for fibrosis. We conducted legal due diligence on the target company and reviewed the transaction documentation on behalf of the investors.